Focus: Prenosis is an AI-powered precision diagnostics company based in Chicago developing biomarker-driven tools to identify disease endotypes and guide clinical decision-making. The company operates in the early-stage diagnostics space with a focus on critical care indications.
Profile data last refreshed 10h ago · AI intelligence enriched 2w ago
Prenosis is a high-risk, high-upside early-stage bet for technologists and diagnostics specialists willing to trade stability for early equity and domain-building opportunity.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Prenosis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Prenosis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles